

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS
05 MAR -8 PM 4:17

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Quinn Gillespie & Associates			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1133 Connecticut Ave. NW 5th Floor City Washington State/Zip (or Country) DC 20036			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Andrew Poe	Telephone _____	E-mail (optional) apoe@quinn-gillespie.com	5. Senate ID # _____
7. Client Name <input type="checkbox"/> Self Aventis Pharmaceuticals, Inc.			6. House ID # _____

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobby

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$60,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
--	---

Signature 

Date **3/3/2005**

Registrant Name: Quinn Gillespie & Associates

Client Name: Aventis Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)


16. Specific Lobbying issues
A resolution to name March "Deep Vein Thrombosis (DVT) Month."

17. House(s) of Congress and Federal agencies contacted Check if None
**Department of Health & Human Services
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Andrews, Bruce	
Connaughton, Jeff	
Hacker, Mike	Communications Dir. (Rep. John Dingell)
Hoppe, Dave	
Hussey, Michael	
Hynes, Scott	
Iturregui, Juan Carlos	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Aventis Pharmaceuticals, a part of sanofi-aventis Group. Please see attached.

Signature 

Date **3/3/2005**

LD-2 Yr. End 2004
Registrant: Quinn Gillespie & Associates
Client: Aventis Pharmaceuticals, Inc.

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Aventis SA is a stock corporation under French commercial law, headquartered in Strasbourg, France and Aventis Pharmaceuticals is part of Aventis SA. Aventis Pharmaceuticals has an interest in enhancing awareness of the health hazards of deep vein thrombosis and pulmonary embolism as a leading cause of preventable deaths in this country.

Registrant Name: Quinn Gillespie & AssociatesClient Name: Aventis Pharmaceuticals, Inc.

Item	Description	Data
18a	Lobbyist Name	James Melvin, Harriet
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Lampkin, Marc
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Lugar, Dave
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Maduros, Nicolas
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Ortiz, Manuel
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Quinn, John M.
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Thomas, Marti
18b	Covered Official Position	
18c	New Lobbyist	No

